Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
2 drugs in development
By Therapeutic Area
top 3
R&D Momentum
57/100
Pipeline Velocity
25/100
Trial Completion Rate
96/100
Pipeline Concentration
33/100
Pipeline Freshness
32/100
Strategic Signals
Activity
Last 14 days
Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Limosilactobacillus Reuteri on Crying and Fussing Time in Infants With Infantile Colic
The Impact of Capsule Postbiotic Supplementation on Physiological and Metabolic Parameters and Dietary Tolerability in Healthy Volunteers
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)